• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Search for a concentration-effect curve of adalimumab in ankylosing spondylitis patients.

作者信息

Marsman A F, Kneepkens E L, Ruwaard J, Wei J C, Nurmohamed M T, van Denderen C, van der Horst-Bruinsma I E, Rispens T, Wolbink G

机构信息

a Amsterdam Rheumatology and Immunology Centre , location Reade, Amsterdam , The Netherlands.

b Division of Allergy , Immunology and Rheumatology, Chung Shan Medical University Hospital , Taichung , Taiwan.

出版信息

Scand J Rheumatol. 2016 Jul;45(4):331-4. doi: 10.3109/03009742.2015.1114666. Epub 2016 Jan 4.

DOI:10.3109/03009742.2015.1114666
PMID:26727457
Abstract
摘要

相似文献

1
Search for a concentration-effect curve of adalimumab in ankylosing spondylitis patients.寻找强直性脊柱炎患者中阿达木单抗的浓度-效应曲线。
Scand J Rheumatol. 2016 Jul;45(4):331-4. doi: 10.3109/03009742.2015.1114666. Epub 2016 Jan 4.
2
Persistence of Infliximab in Circulation for 7 Years?
Clin Chem. 2015 Nov;61(11):1420-1. doi: 10.1373/clinchem.2015.242024.
3
Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis.肥胖会降低强直性脊柱炎患者中阿达木单抗的临床疗效和血药浓度。
Clin Exp Rheumatol. 2017 Jan-Feb;35(1):145-148. Epub 2016 Nov 13.
4
Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab.用依那西普或阿达木单抗治疗的强直性脊柱炎患者的药物留存率和临床结果比较
Scand J Rheumatol. 2018 Mar;47(2):122-126. doi: 10.1080/03009742.2017.1330419. Epub 2017 Jul 26.
5
Early Adalimumab and Anti-Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients.早期阿达木单抗和抗阿达木单抗抗体水平预测强直性脊柱炎患者的原发性无应答。
Clin Transl Sci. 2020 May;13(3):547-554. doi: 10.1111/cts.12738. Epub 2020 Feb 13.
6
Transaminase elevation secondary to the use of adalimumab.
Reumatol Clin. 2014 Jul-Aug;10(4):265-6. doi: 10.1016/j.reuma.2013.11.010. Epub 2014 Jan 29.
7
Lobular capillary hemangioma in a patient with ankylosing spondylitis using adalimumab: an exuberant presentation.使用阿达木单抗的强直性脊柱炎患者出现小叶性毛细血管瘤：一种表现旺盛的情况。
An Bras Dermatol. 2019 Nov-Dec;94(6):751-753. doi: 10.1016/j.abd.2019.02.004. Epub 2019 Oct 26.
8
Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab.韩国强直性脊柱炎患者外周疾病的发生频率及阿达木单抗的疗效。
Int J Rheum Dis. 2020 Aug;23(9):1175-1183. doi: 10.1111/1756-185X.13917. Epub 2020 Jul 29.
9
Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.强直性脊柱炎评估研究工作组确定的、接受抗TNFα药物治疗的强直性脊柱炎患者部分缓解的预测因素。
Reumatismo. 2014 Nov 6;66(3):208-14. doi: 10.4081/reumatismo.2014.756.
10
Adalimumab Therapy Restores the Gut Microbiota in Patients With Ankylosing Spondylitis.阿达木单抗治疗可恢复强直性脊柱炎患者的肠道微生物群。
Front Immunol. 2021 Sep 1;12:700570. doi: 10.3389/fimmu.2021.700570. eCollection 2021.

引用本文的文献

1
High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis.高 BMI 与轴性脊柱关节炎患者 TNF-α 抑制剂血清谷浓度较低和疾病活动度较高相关。
Arthritis Res Ther. 2023 Oct 17;25(1):202. doi: 10.1186/s13075-023-03187-4.
2
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases.阿达木单抗血清水平与抗药物抗体：与炎症性关节疾病的治疗反应和药物生存的关联。
Rheumatology (Oxford). 2024 May 3;63(6):1746-1755. doi: 10.1093/rheumatology/kead525.
3
Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider.
炎症性风湿和肌肉骨骼疾病中生物制药的治疗药物监测：系统文献回顾为 EULAR 考虑要点提供信息。
RMD Open. 2022 Jun;8(2). doi: 10.1136/rmdopen-2022-002216.
4
Early Adalimumab and Anti-Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients.早期阿达木单抗和抗阿达木单抗抗体水平预测强直性脊柱炎患者的原发性无应答。
Clin Transl Sci. 2020 May;13(3):547-554. doi: 10.1111/cts.12738. Epub 2020 Feb 13.
5
Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study.在炎症性关节疾病患者中，培戈洛珠单抗血清水平、抗药物抗体与治疗反应之间的相关性：来自 NOR-DMARD 研究的数据。
Arthritis Res Ther. 2019 Nov 29;21(1):256. doi: 10.1186/s13075-019-2009-5.
6
Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis.TNF 抑制剂在轴性脊柱关节炎中剂量减少与标准剂量的非劣效性。
Arthritis Res Ther. 2019 Jan 8;21(1):11. doi: 10.1186/s13075-018-1772-z.